The DYSF Gene and Renal Cell Carcinoma: A New Prognostic Biomarker?
There is great interest in evaluating the link between hypercalcemia and prognosis in ccRCC by researching the genes that influence calcium levels.
Kidney Cancer
Should Age Be a Barrier to Clinical Trial Participation for Older Patients With Metastatic Renal Cell Carcinoma?
A retrospective study compared older patients with mRCC with younger ones to determine if age and potential comorbidities is a barrier to clinical trial participation.
CheckMate 214: Long-Term Results Confirm Superiority of Nivolumab Plus Ipilimumab for mRCC
Superiority of the regimen was shown in intermediate- and poor-risk groups, as well as in intention-to-treat populations.
Elevated NLR Combined With Low Sodium Predicts Worse Survival in RCC
At RCC diagnosis, patients with an neutrophil-lymphocyte ratio (NLR) above 3.0 and concomitant hyponatremia had a significant 2.8-fold increased risk of death compared with those who had an NLR of 3.0 or lower and normal sodium levels, a Danish study found.
Axitinib Did Not Meet Study End Point in mRCC, but Dosing Found Feasible
Although study failed to meet its primary endpoint, the researchers suggest approach could be used in clinical practice.
Looking at Survival Differently in Patients With Metastatic Kidney Cancer
Conditional survival may more accurately assess prognosis than traditional survival for patients with metastatic kidney cancer, but the metric is not without its caveats.
Right-Sided RCC Predicts Better Outcomes in Patients With Larger Tumors
Among patients undergoing surgery for 10 cm or larger renal cell carcinoma tumors, right-sided tumors are independently associated with improved cancer-specific survival compared with left-sided tumors, a study found.
Upfront Immune Checkpoint Inhibition Called New Metastatic RCC Standard of Care
Updated European Association of Urology guidelines recommend pembrolizumab plus axitinib or ipilimumab plus nivolumab for the first-line treatment of metastatic clear-cell renal cell carcinoma.
Nivolumab Shows Long-Term Survival Benefit in RCC, Other Cancers
In a post hoc analysis of a phase 1 trial, nivolumab treatment was associated with long-term survival in a subset of patients with advanced renal cell carcinoma, melanoma, and non-small cell lung cancer.
Guideline-Based Hematuria Evaluation May Up Risk of Secondary Cancers
Uniform use of computed tomography for hematuria workups marginally increases detection of urinary tract cancers while raising the risk for secondary cancers from imaging-associated radiation, researchers concluded.
Next post in Bladder Cancer
